Patient Trials Planned or Underway for 2 Oral ALS Therapies, Denali Says

Patient Trials Planned or Underway for 2 Oral ALS Therapies, Denali Says

308832

Patient Trials Planned or Underway for 2 Oral ALS Therapies, Denali Says

Early trials in healthy adults supported the safety and tolerability of two potential oral therapies for amyotrophic lateral sclerosis (ALS) — DNL343 to prevent the cellular stress that can promote toxic protein granules, and DNL788 to block a protein linked to brain inflammation — Denali Therapeutics reported. A Phase 1b trial in ALS patients is underway for DNL343, and a Phase 2 trial of DNL788 in patients is planned for early next year. Work in animal models and…

You must be logged in to read/download the full post.